Asahi shares mark weekly slide after cyberattack halts production
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) has filed a formal request for the examination of its patent application for SIRT6 variants targeting Non-Alcoholic Steatohepatitis (NASH) in China, the company announced Friday.
The patent application covers proprietary variants of the SIRT6 gene designed to address NASH, a progressive liver disease with limited treatment options. This move strengthens Genflow’s intellectual property portfolio in one of the world’s largest healthcare markets.
"The filing of this examination request in China represents another significant step in protecting our technology," said Dr. Eric Leire, CEO of Genflow, according to the company’s press release.
Genflow, which describes itself as the only publicly listed longevity company in Europe, is developing gene therapies aimed at decelerating the aging process. The company’s lead compound, GF-1002, delivers a centenarian variant of the SIRT6 gene.
The company began a 12-month proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs in March 2025. Genflow also plans to initiate a clinical trial exploring potential benefits of GF-1002 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) later this year.
NASH is characterized by liver inflammation and damage caused by fat buildup in the liver. It represents a significant unmet medical need globally, as effective treatments remain limited.
The patent examination filing is part of Genflow’s strategy to secure intellectual property protection across key markets as it advances its research into SIRT6-based therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.